Live Breaking News & Updates on Drug Repurposing|Page 16
Stay updated with breaking news from Drug repurposing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celastrol shows potential anti-SARS-CoV-2 activity On the 11th of March 2020, the World Health Organization (WHO) announced Coronavirus Disease 2019 (COVID-19) to be a pandemic. This disease is highly infectious and is caused by a novel positive-stranded β-coronavirus, namely, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Globally, this virus has had a devastating effect on public health and the economy. Scientists believe that only the discovery of effective vaccines and potential drugs can contain the ongoing pandemic. Despite the commencement of vaccination programs in many countries, there is a need for more immunization strategies as the demand is exceptionally high, and there are certain limitations in the mass production of vaccines. ....
(Volker Lannert/University of Bonn) Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19. The research and license pact, financials of which were not made public, focuses on the antiviral inhibitor of SARS-CoV-2, TNX-3500 (aka sangivamycin, formerly OYA1), which Tonix believes can hit back against the pandemic virus and “potentially other viral disorders.” The active ingredient of the drug has, in fact, been studied for safety in humans in prior research on cancer patients at the U.S. National Cancer Institute. New York-based OyaGen says very early tests of TNX-3500 have shown it to be 65 times more potent in head-to-head comparisons at inhibiting SARS-CoV-2 than remdesivir, the active ingredient of Gilead’s Ebola-cum-COVID drug Veklury. Combining the two also saw “additive activity against SARS-CoV-2 in cell culture infectivity,” according to the preclinical biotech, though these result ....
COVID-19 in Europe – one year on from the first case drugtargetreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drugtargetreview.com Daily Mail and Mail on Sunday newspapers.
Researchers use AI to identify drugs that could be repurposed for Alzheimer’s Eli Lilly s JAK inhibitor Olumiant identified as a potential treatment for repurposing Researchers from Harvard Medical School and Massachussetts General Hospital have revealed which drugs could be potentially repurposed as possible treatments for Alzheimer’s disease using artificial intelligence (AI). The research team developed an AI-based method that enabled them to screen US Food and Drug Administration (FDA) approved medications for their potential as repurposed Alzheimer’s treatments. The study, published in Nature Communications, used a framework called DRIAD (Drug Repurposing in Alzheimer’s Disease) which uses machine learning to measure what happens to human brain neural cells when treated with a drug. ....
Mar 8, 2021 8:55am Researchers from Harvard University and Massachusetts General Hospital suggested JAK inhibitors may be useful in treating Alzheimer s after using machine learning to model the response of brain neural cells to a variety of drugs. (sdecoret/iStock/Getty Images Plus) Could janus kinase (JAK) inhibitors like Eli Lilly’s rheumatoid arthritis drug Olumiant be repurposed to treat Alzheimer’s disease? Researchers at Harvard University and Massachusetts General Hospital have set out to find the answer to that question with a new clinical trial that was born from artificial intelligence. The researchers used a type of AI called machine learning to identify existing drugs that might be able to prevent neuronal death in Alzheimer’s. The screen pulled up a list of 15 FDA-approved drugs as candidates for repurposing in Alzheimer’s, and five of them were JAK inhibitors, they reported in the journal Nature Communications. ....